Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation

Eleanor Burnett, Atif Riaz, Palwasha Anwari, Theingi Win Myat, Tyler P. Chavers, Nabila Talat, Najibullah Safi, Nway Nway Thinn Aung, Margaret M. Cortese, Shazia Sultana, Akmal Samsor, Hlaing Myat Thu, Nasir Saleem Saddal, Sohrab Safi, Htin Lin, Saqib Hamid Qazi, Helah Safi, Asad Ali, Umesh D. Parashar, Jacqueline E. Tate

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Rotavirus vaccines have substantially decreased rotavirus hospitalizations in countries where they have been implemented. In some high- and middle-income countries, a low-level of increased risk of intussusception, a type of acute bowel obstruction, has been detected following rotavirus vaccination. However, no increased risk of intussusception was found in India, South Africa, or a network of 7 other African countries. We assessed the association between a 2-dose monovalent rotavirus vaccine (Rotarix) and intussusception in 3 early-adopter low-income Asian countries – Afghanistan, Myanmar, and Pakistan. Children <12 months of age admitted to a sentinel surveillance hospital with Brighton level 1 intussusception were eligible for enrollment. We collected information about each child's vaccination status and used the self-controlled case series method to calculate the relative incidence of intussusception 1–7 days, 8–21 days, and 1–21 days following each dose of vaccine and derived confidence intervals with bootstrapping. Of the 585 children meeting the analytic criteria, the median age at intussusception symptom onset was 24 weeks (IQR: 19–29). Overall, 494 (84 %) children received the first Rotarix dose and 398 (68 %) received the second dose. There was no increased intussusception risk during any of the risk periods following the first (1–7 days: 1.01 (95 %CI: 0.39, 2.60); 8–21 days: 1.37 (95 %CI: 0.81, 2.32); 1–21 days: 1.28 (95 %CI: 0.78, 2.11)) or second (1–7 days: 0.81 (95 %CI: 0.42, 1.54); 8–21 days: 0.77 (95 %CI: 0.53, 1.16); 1–21 days: 0.78 (95 %CI: 0.53, 1.16)) rotavirus vaccine dose. Our findings are consistent with other data showing no increased intussusception risk with rotavirus vaccination in low-income countries and add to the growing body of evidence demonstrating safety of rotavirus vaccines.

Original languageEnglish
Pages (from-to)7220-7225
Number of pages6
Issue number48
Publication statusPublished - 22 Nov 2023


  • Intussusception
  • Rotavirus vaccine
  • Vaccination


Dive into the research topics of 'Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation'. Together they form a unique fingerprint.

Cite this